IRIS
LOPETUSO, Loris Riccardo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.080
AS - Asia 2.637
EU - Europa 2.230
SA - Sud America 539
AF - Africa 57
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 8
Totale 10.563
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.956
SG - Singapore 1.445
IT - Italia 516
IE - Irlanda 482
RU - Federazione Russa 465
BR - Brasile 412
CN - Cina 368
VN - Vietnam 327
SE - Svezia 274
DE - Germania 122
HK - Hong Kong 101
BD - Bangladesh 97
GB - Regno Unito 82
CA - Canada 67
AR - Argentina 56
IN - India 48
JP - Giappone 40
NL - Olanda 37
AT - Austria 35
FR - Francia 33
MX - Messico 31
ID - Indonesia 26
ES - Italia 25
IQ - Iraq 24
PL - Polonia 23
EC - Ecuador 22
FI - Finlandia 21
CO - Colombia 20
TR - Turchia 18
BE - Belgio 17
RO - Romania 17
TW - Taiwan 17
ZA - Sudafrica 17
PK - Pakistan 16
IR - Iran 14
UA - Ucraina 14
TH - Thailandia 12
AU - Australia 11
BG - Bulgaria 11
HR - Croazia 11
SA - Arabia Saudita 11
EG - Egitto 10
MY - Malesia 10
KR - Corea 9
PE - Perù 9
PH - Filippine 9
NP - Nepal 8
CH - Svizzera 7
JM - Giamaica 7
UZ - Uzbekistan 7
CL - Cile 6
LU - Lussemburgo 6
TN - Tunisia 6
AZ - Azerbaigian 5
EU - Europa 5
VE - Venezuela 5
DZ - Algeria 4
LT - Lituania 4
PA - Panama 4
PY - Paraguay 4
RS - Serbia 4
UY - Uruguay 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
BH - Bahrain 3
CR - Costa Rica 3
DK - Danimarca 3
ET - Etiopia 3
HU - Ungheria 3
MA - Marocco 3
QA - Qatar 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GR - Grecia 2
HN - Honduras 2
JO - Giordania 2
KE - Kenya 2
KG - Kirghizistan 2
KZ - Kazakistan 2
ME - Montenegro 2
NG - Nigeria 2
NO - Norvegia 2
PT - Portogallo 2
SC - Seychelles 2
TZ - Tanzania 2
AM - Armenia 1
BB - Barbados 1
BF - Burkina Faso 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BS - Bahamas 1
CY - Cipro 1
GH - Ghana 1
GT - Guatemala 1
GY - Guiana 1
Totale 10.551
Salva come PNG Salva come JPEG
Città #
Singapore 948
Chandler 766
San Jose 582
Dublin 481
Ashburn 386
Dallas 267
Princeton 235
Jacksonville 191
Santa Clara 116
Altamura 114
Council Bluffs 112
Los Angeles 104
Beijing 96
Dong Ket 93
Ho Chi Minh City 92
Hong Kong 90
Wilmington 86
Redondo Beach 66
Ann Arbor 57
New York 55
Rome 54
Buffalo 53
Hanoi 52
Moscow 50
Chieti 43
The Dalles 42
Nuremberg 35
São Paulo 34
Frankfurt am Main 33
Tokyo 31
Pescara 30
Falls Church 27
Atlanta 25
Orem 25
Chicago 24
Montreal 23
Munich 23
London 22
Taranto 20
Brussels 17
Memphis 17
Norwalk 17
Teramo 16
Rio de Janeiro 15
San Francisco 15
Stockholm 14
Denver 13
Hefei 13
Milan 13
Pune 12
Amsterdam 11
Guangzhou 11
Houston 11
Phoenix 11
Xitun 11
Baghdad 10
Cluj-Napoca 10
Columbus 10
Manchester 10
Mexico City 10
Sofia 10
Tongling 10
Toronto 10
Vienna 10
Boardman 9
Brasília 9
Brooklyn 9
Edinburgh 9
Helsinki 9
Warsaw 9
Belo Horizonte 8
Bologna 8
Calgary 8
Curitiba 8
Da Nang 8
Dhaka 8
Palermo 8
Washington 8
Zagreb 8
Bari 7
Guayaquil 7
Johannesburg 7
Lappeenranta 7
Macerata 7
Porto Alegre 7
Tashkent 7
Ankara 6
Biên Hòa 6
Chennai 6
Guglionesi 6
Haiphong 6
Jakarta 6
Kingston 6
Kuala Lumpur 6
Lima 6
Naples 6
Salvador 6
Seoul 6
Tehran 6
Bangkok 5
Totale 6.148
Salva come PNG Salva come JPEG
Nome #
Nodular lymphoid hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome? 399
Bacillus clausii for the treatment of acute diarrhea in children: A systematic review and meta-analysis of randomized controlled trials 215
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): Preliminary results from a retrospective cohort study 188
Assessment of crohn’s disease activity: Magnetic resonance enterography in comparison with clinical and endoscopic evaluations 156
13C-octanoic acid breath test to study gastric emptying time 141
Anti-tumor necrosis factor α therapy associates to type 17 helper T lymphocytes immunological shift and significant microbial changes in dextran sodium sulphate colitis 139
The use of anti-spasmodics in the treatment of irritable bowel syndrome: Focus on otilonium bromide 138
Bacillus clausii and gut homeostasis: state of the art and future perspectives 122
Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease 120
Role of Helicobacter pylori infection on nutrition and metabolism 117
Akkermansia muciniphila: Key player in metabolic and gastrointestinal disorders 114
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab 112
A transition clinic model for inflammatory bowel disease between two tertiary care centers: outcomes and predictive factors 111
European guideline on indications, performance, and clinical impact of hydrogen and methane breath tests in adult and pediatric patients: European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Neurogastroenterology and Motility, and European Society for Paediatric Gastroenterology Hepatology and Nutrition consensus 108
Characterization of sarcopenia in an IBD population attending an Italian gastroenterology tertiary center 107
Esophageal microbiome signature in patients with Barrett’s esophagus and esophageal adenocarcinoma 106
A modern multidisciplinary approach to the treatment of enterocutaneous fistulas in Crohn’s disease patients 102
Specific 13C functional pathways as diagnostic targets in gastroenterology breath-tests: tricks for a correct interpretation 101
Interleukin 1β Blockade Reduces Intestinal Inflammation in a Murine Model of Tumor Necrosis Factor-Independent Ulcerative Colitis 101
Towards a disease-associated common trait of gut microbiota dysbiosis: The pivotal role of Akkermansia muciniphila 99
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 99
Diagnosis of Cholangiocarcinoma: The New Biological and Technological Horizons 98
Coordinated Multi-Language Translation of A Validated Symptom Questionnaire for Carbohydrate Intolerances: A Practical Structured Procedure 97
Proteobacteria: A common factor in human diseases 97
A novel model of colitis-associated cancer in SAMP1/YitFc mice with Crohn's disease-like ileitis 96
Actinobacteria: A relevant minority for the maintenance of gut homeostasis 96
Beyond the HLA Genes in Gluten-Related Disorders 96
Role of yeasts in healthy and impaired gut microbiota: The gut mycome 95
Food components and dietary habits: Keys for a healthy gut microbiota composition 94
Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: Emerging role for ‘gut barrier protectors’ in IBD? 93
Assessment of neurological manifestations in hospitalized patients with COVID-19 93
Characterization of mucosal cytokine profile in ulcerative colitis patients under conventional and anti-TNF-a treatment 92
Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease 91
The gastrointestinal microbiome - Functional interference between stomach and intestine 90
Flexible colonoscopy in mice to evaluate the severity of colitis and colorectal tumors using a validated endoscopic scoring system 89
Gut microbiota profiling and gut-brain crosstalk in children affected by pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections 88
Bacteriocins and bacteriophages: Therapeutic weapons for gastrointestinal diseases? 86
Prevalence of cervical HPV and attitude towards cervical screening in IBD patients under immunomodulatory treatment: A multidisciplinary management experience 84
Ulcerative colitis 84
Opposing functions of classic and novel IL-1 family members in gut health and disease 84
Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide 84
Anti-TNF-α-induced psoriasiform lesions in IBD: An abnormal immune activation or a 'patchy cutaneous' immune suppression? 84
The gut barrier: New acquisitions and therapeutic approaches 83
Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises from a First Meta-Analysis 83
Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis 83
Tricks for interpreting and making a good report on hydrogen and 13C breath tests 82
Locally injected Infliximab ameliorates murine DSS colitis: Differences in serum and intestinal levels of drug between healthy and colitic mice 82
The impact of COVID-19 pandemic on IBD endoscopic procedures in a high-volume IBD Center 82
Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection—single versus multiple infusions 80
Commensal Clostridia: Leading players in the maintenance of gut homeostasis 80
Role and mechanisms of action of Escherichia coli nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update 79
Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases 79
Gut microbiota modulation and mucosal immunity: Focus on Rifaximin 78
The innate and adaptive immune system as targets for biologic therapies in inflammatory bowel disease 78
Commentary to “safety, clinical response, and microbiome findings following fecal microbiota transplant in children with inflammatory bowel disease” 77
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 77
The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin 77
Gut Virome and Inflammatory Bowel Disease 76
Microbiota and inflammatory bowel disease: An update 76
European Crohn's and colitis organisation topical review on treatment withdrawal ['exit strategies'] in inflammatory bowel disease 76
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications 76
Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review 75
Unfolded protein response: An essential element of intestinal homeostasis and a potential therapeutic target for inflammatory bowel disease 75
Gut microbiota and inflammatory bowel disease: So far so gut! 75
Liver Injury, Endotoxemia, and Their Relationship to Intestinal Microbiota Composition in Alcohol-Preferring Rats 75
Dietary magnesium alleviates experimental murine colitis through upregulation of the transient receptor potential melastatin 6 channel 75
Can we predict the efficacy of anti-TNF-α agents? 75
Direct effect of infliximab on intestinal mucosa sustains mucosal healing: Exploring new mechanisms of action 74
IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair 74
Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders 73
High dose amoxicillin-based first line regimen is equivalent to sequential therapy in the eradication of H. Pylori infection 73
Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment 73
Human herpesvirus 8-associated colonic Kaposi's sarcoma during vedolizumab treatment in ulcerative colitis: A case report and review of the literature 72
The therapeutic management of gut barrier leaking: The emerging role for mucosal barrier protectors 72
Infliximab does not increase colonic cancer risk associated to murine chronic colitis 71
Bariatric procedures and microbiota: patient selection and outcome prediction 71
Coeliac disease under a microscope: Histological diagnostic features and confounding factors 71
Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission 71
Intestinal permeability in physiological and pathological conditions: Major determinants and assessment modalities 70
Prevalence of severe irritable bowel syndrome among Italian adults. A meta-analysis 70
Epidemiological evaluation of acute gastroenteritis and therapeutic approaches in Middle East Countries 70
Gelatin tannate and tyndallized probiotics: a novel approach for treatment of diarrhea 70
Pre- and posttherapy assessment of intestinal soluble mediators in IBD: Where we stand and future perspectives 69
Microbes and Alzheimer' disease: Lessons from H. Pylori and GUT microbiota 69
The interplay between gut microbiota and the unfolded protein response: Implications for intestinal homeostasis preservation and dysbiosis-related diseases 68
Epidemiology of inflammatory bowel disease in the Republic of San Marino: The “EPIMICI – San Marino” study 68
Considering gut microbiota disturbance in the management of Helicobacter pylori infection 68
Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for C. difficile infection during the COVID-19 pandemic: A prospective cohort study 67
Hypoxic Functional Regulation Pathways in the GI Tract: Focus on the HIF-1α and Microbiota's Crosstalk 66
The “dica” endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists 66
Microparticles produced by activated platelets carry a potent and functionally active angiogenic signal in subjects with crohn’s disease 66
Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma 66
The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications 65
Bile Acid-Related Regulation of Mucosal Inflammation and Intestinal Motility: From Pathogenesis to Therapeutic Application in IBD and Microscopic Colitis 64
Intestinal gas production and gastrointestinal symptoms: from pathogenesis to clinical implication 64
Relationship between oral microbiota and periodontal disease: A systematic review 64
Epithelial-specific Toll-like Receptor (TLR)5 Activation Mediates Barrier Dysfunction in Experimental Ileitis 64
The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease 64
Fighting the Hype for Predictors of Efficacy in Inflammatory Bowel Disease 64
Gut microbiota during dietary restrictions: New insights in non-communicable diseases 64
Totale 9.021
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.754
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.754
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022705 53 3 3 118 20 16 11 28 54 39 60 300
2022/20231.882 241 337 89 224 95 348 120 143 169 18 81 17
2023/2024849 53 36 47 51 36 186 235 87 14 37 13 54
2024/20251.774 158 348 191 54 36 112 82 96 305 84 163 145
2025/20264.521 257 152 583 463 382 167 699 287 564 413 397 157
2026/2027563 563 0 0 0 0 0 0 0 0 0 0 0
Totale 11.076